l1OM oARcPSD|327 b 441
b 69
Study Guide For
b b b
Pharmacotherapeutics For Advanced Practice: Ab b b b
PracticalApproach 5th Edition | Advanced
b b b b b b
Pharmacology Review Questions& Answers |
b b b b b b
APRN Exam Prep 2025/2026
b b b b
, lOMoARcPSD|327 b441 b69
TABLE OF CONTENT
b b
o Chapter 1: Issues for the Practitioner in Drug Therapy
b b b b b b b b
o Chapter 2: Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
b b b b b b b b
o Chapter 3: Impact of Drug Interactions and Adverse Events on Therapeutics
b b b b b b b b b b
o Chapter 4: Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
b b b b b b b b b
o Chapter 5: Pharmacotherapy Principles in Older Adults
b b b b b b
o Chapter 6: Principles of Antimicrobial Therapy
b b b b b
o Chapter 7: Pharmacogenomics b b
o Chapter 8: The Economics of Pharmacotherapeutics
b b b b b
o Chapter 9: Principles of Pharmacology in Pain Management
b b b b b b b
o Chapter 10: Pain Management in Opioid Use Disorder (OUD) Patients
b b b b b b b b b
o Chapter 11: Cannabis and Pain Management
b b b b b
o Chapter12: Dermatitis b b
o Chapter 13: Bacterial, Fungal, and Viral Infections of the Skin
b b b b b b b b b
o Chapter14: Psoriasis b b
o Chapter15: AcneVulgaris and Rosacea
b b b b b
o Chapter 16: Ophthalmic Disorders
b b b
o Chapter17: OtitisMedia and OtitisExterna
b b b b b b
o Chapter18: Hypertension b b
o Chapter19: Hyperlipidemia b b
o Chapter 20: Chronic Stable Angina and Myocardial Infarction
b b b b b b b
o Chapter 21: Heart Failure b b b
o Chapter22: Arrhythmias b b
o Chapter 23: Respiratory Infections
b b b
o Chapter 24: Asthma and Chronic Obstructive Pulmonary Disease
b b b b b b b
o Chapter 25: Gastric, Functional and Inflammatory Bowel Disorders
b b b b b b b b
o Chapter 26: Gastroesophageal Reflux Disease and Peptic Ulcer Disease
b b b b b b b b
o Chapter27:LiverDiseases b b b
o Chapter 28: Urinary Tract Infection
b b b b
o Chapter 29: Prostatic Disorders and Erectile Dysfunction
b b b b b b b
o Chapter30: Overactive Bladder b b b
o Chapter 31: Sexually Transmitted Infections
b b b b
o Chapter 32: Osteoarthritis and Gout
b b b b
o Chapter33: Osteoporosis b b
o Chapter 34: Rheumatoid Arthritis
b b b
o Chapter35: Headaches b b
o Chapter 36: Seizure Disorders
b b b
o Chapter 37: Alzheimer’s Disease
b b b
o Chapter 38: Parkinson Disease
b b b
o Chapter 39: Major Depressive Disorder and Bipolar Disorders
b b b b b b b
o Chapter 40: Anxiety Disorders b b b
o Chapter 41: Sleep Disorders b b b
o Chapter 42: Attention Deficit Hyperactivity Disorder
b b b b b
o Chapter 43: Substance Use Disorders
b b b b
o Chapter 44: Diabetes Mellitusb b b
o Chapter 45: Thyroid and Parathyroid Disorders
b b b b b
o Chapter 46: Allergies and Allergic Reactions o
b b b b b b
Chapter 47: Human Immunodeficiency Virus o
b b b b b b
Chapter 48: Organ Transplantation
b b b b
o Chapter 49: Pharmacotherapy for Select Thromboembolic Disorders
b b b b b b
o Chapter50: Anemias b b
o Chapter51:Immunizations b b
o Chapter 52: Smoking Cessation
b b b
o Chapter53: Weight Loss b b b
o Chapter54: Contraception b b
, lOMoARcPSD|327 b441 b69
o Chapter55: Menopause b b
o Chapter56: Vaginitis b b
Chapter 1Issuesforthe Practitioner in Drug Therapy
b b b b b b b b
MULTIPLECHOICE b
1. Nursepractitioner prescriptive authorityisregulated by:
b b b b b b
A. TheNational Councilof StateBoards of Nursing
b b b b b b b
B. TheU.S.DrugEnforcement Administration
b b b b
C. The State Board ofNursing for each state
b b b b b b b
D. The State Board of Pharmacy b b b b
ANS: C b PTS: 1
2. PhysicianAssistant (PA) prescriptiveauthority is regulated by:
b b b b b b b
A. TheNational Councilof StateBoards of Nursing
b b b b b b b
B. TheU.S.DrugEnforcement Administration
b b b b
C. The State Board of Nursing b b b b
D. The State Board of Medical Examiners
b b b b b
ANS: D b PTS: 1
3. Clinicaljudgment inprescribingincludes:
b b b b
A. Factoring inthe costto the patient ofthemedication prescribed b b b b b b b b b b
B. Always prescribing the newest medication available for the disease process
b b b b b b b b b
C. Handing out drug samples to poor patients b b b b b b
D. Prescribingall genericmedications tocut costs b b b b b b
ANS: A b PTS: 1
4. Criteriafor choosingan effectivedrugforadisorder include:
b b b b b b b b b
A. Askingthepatientwhatdrugtheythink wouldworkbestforthem
b b b b b b b b b b b
B. Consultingnationallyrecognizedguidelinesfordisease management b b b b b b
C. Prescribing medications that are available as samples before writing a prescription b b b b b b b b b b
D. FollowingU.S.Drug EnforcementAdministration(DEA)guidelinesfor b b b b b b b
prescribing
b
ANS: B b PTS: 1
5. Nurse practitioner practice maythrive under health-carereform due to:
b b b b b b b b b
A. The demonstrated ability of nurse practitioners to control costs and improve patient
b b b b b b b b b b b
outcomes
b
B. Thefactthatnursepractitionerswillbeabletopracticeindependently
b b b b b b b b b b
C. The fact that nurse practitioners will have full reimbursement under health-care
b b b b b b b b b b
reform
b
D. The abilityto shiftaccountabilityforMedicaidtothestate level
b b b b b b b b b b
ANS: A b PTS: 1
, lOMoARcPSD|327 b441 b69
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
b b b b b b
MULTIPLECHOICE b
1. Apatient’snutritionalintakeandlabworkreflectshypoalbuminemia.Thisis criticalto
b b b b b b b b b b b b
bprescribingbecause:
A. Distribution of drugs totargettissue may beaffected b b b b b b b b
B. Thesolubility ofthe drug will not matchthe siteofabsorption
b b b b b b b b b b b
C. Therewill beless freedrugavailable togenerate aneffect b b b b b b b b b b
D. Drugsbound toalbumin arereadilyexcreted bythekidney b b b b b b b b b
ANS: A b PTS: 1
2. Drugs that haveasignificantfirst-passeffect:
b b b b b b
A. Mustbegivenbythe enteral(oral)routeonly b b b b b b b b
B. Bypassthehepaticcirculation b b b
C. Are rapidly metabolized bytheliver and mayhave little if anydesired action
b b b b b b b b b b b b b
D. Areconvertedbythe livertomoreactiveandfat-solubleforms
b b b b b b b b b b
ANS: C b PTS: 1
3. Theroute ofexcretionof avolatiledrug willlikelybe:
b b b b b b b b b b
A. Thekidneys b
B. Thelungs b
C. The bile and feces b b b
D. The skin b
ANS: B b PTS: 1
4. Medroxyprogesterone (DepoProvera)isprescribedIM tocreatea storagereservoir ofthe drug. b b b b b b b b b b b b b
Storagereservoirs:
b b
A. Assurethat the drug willreach its intendedtarget tissue b b b b b b b b b
B. Arethe reasonfor giving loadingdoses b b b b b b
C. Increasethelengthoftimea drug isavailableandactive b b b b b b b b b b
D. Aremost common in collagentissues b b b b b
ANS: C b PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledgeof thedrug’s:
b b b b b b b b b b b b b b
A. Propensitytogotothetarget receptor b b b b b b
B. Biologicalhalf-life b
C. Pharmacodynamics
D. Safetyand sideeffects b b b
ANS: B b PTS: 1
6. Azithromycindosingrequiresthefirstday’sdosebetwicethose ofthe other4 days ofthe b b b b b b b b b b b b b b b b
prescription.Thisisconsideredaloadingdose.Aloadingdose:
b b b b b b b b b b
A. Rapidly achievesdruglevelsinthetherapeuticrange b b b b b b b
B. Requiresfour tofive half-livesto attain b b b b b b
C. Is influenced by renal function
b b b b